Angelo Carella

Dr. Angelo Carella is a consultant hematologist at Casa di Cura la Madonnina. He is an internationally recognized specialist.

In 1972, he graduated in Medicine from the University of Genoa, where in 1978 he had specialization in Medical Oncology. 

In 1981, Dr. Carella also specialized in clinical and laboratory hematology, and in 1983 he took the exam for the qualification of Chief of Hematology.

From 1973 to 1993, he was the first assistant physician, and then the assistant professor at Ospedale San Pier d'Arena in Genoa.

Since 1994, he is Level I Medical Director. From 1991 to 1997, he was Adjunct Professor at the School of Specialization of the Hematology Department, University of Parma.

From 1997 to 2013, he was Adjunct Professor at the School of Specialization of the Hematology Department, University of Genoa.

From 2001 to 2004, he was the head of the Division of Hematology and Bone Marrow Transplantation Center and director of the Department of Oncology / Hematology at IRCCS Casa Sollievo della Sofferenza in Foggia. 

From 2005 to 2016, he was Director of the Division of Hematology I and Marrow Transplant Center of the hospital IRCCS AOU San Martino-IST in Genoa. 

He actively participated in the realization of the first allogeneic transplant in Italy in 1974 and performed the first autologous transplantation in Europe in 1979. 

He was among the first specialists in the world to study idarubicin in acute leukemia, developing, in 1985, the ICE (Idarubicin, Citarabine and Etoposide) protocol for the treatment of acute myeloid leukemia, currently used internationally.

He was the first to demonstrate the presence of normal stem cells in the peripheral blood of patients with chronic myeloid leukemia after myeloblastic therapy. The same cells have been used as "rescue" after high doses of chemotherapy (Autotransplantation) (Journal of Clinical Oncology 1997; Blood 1999).

He was the first to demonstrate the importance of allogeneic non-myeloablative transplantation (Reduced Intensity Conditioning for Transplant- RICT) (Haematologica 1998, Bone Marrow Transplantation 2001, Blood 2010). 

Since then, this procedure has been used throughout the world and in the vast majority of patients who are going to receive an allogeneic transplant.

He was the first doctor to use "Double Transplant" (autologous transplant followed by non-myeloablative allogeneic transplant - RICT) in metastatic breast cancer and in high-risk blood diseases. 

He demonstrated non-inferiority of conventional therapy compared to the same therapy followed by autologous transplantationin an international randomized trial in high-risk Hodgkin's lymphoma.

He demonstrated that BCR-ABL mutations might be present in patients at high risk for Chronic Myeloid Leukemia already at diagnosis. As a result of that discovery, he recently published a novel therapy hypothesis (Annals of Hematology 2010).

He is a member of the following scientific societies:

• American Society of Clinical Oncology – ASCO; 
• American Society of Hematology – ASH; 
• European Blood and Marrow Transplantation –  EBMT; 
• European Haematology Association – EHA; 
• European School of Hematology – ESH; 
• International Society for Experimental Hematology – SIE; 
• Italian Society of Experimental Hematology – SIES; 
• The New England Cancer Society – Honorary Member: he is one of the founders of the International Workshop on Non-Myeloablative Stem Cell Transplantation – IWNST 

Not so long ago, he published an Editorial on Chronic Myeloid Leukemia in collaboration with Michael Mauro (N.York) and X.Mahon (Bordeaux) in the European Journal of Hematology (HAEMATOLOGICA) and then a "Review Article" on Hodgkin's Lymphoma in collaboration with P. Corradini, U.Vitolo in the German Journal of Hematology (Annals of Hematology).

He has been a part of the Editorial Board and is a reviewer for numerous national and international scientific journals.

He is an Associate Editor of the journal Hematological Oncology and co-editor of:

• book “Chronic Myeloid Leukemia. Biology and Treatment” (Martin Dunitz),
• book ”Bone Marrow Transplantation” (Martin Dunitz)
• book “International Conference on Haematopoietic Stem cell Biology” and Transplantation (ESH, EUROCORD)

He is an editor of: 

• Autologous Stem Cell transplantation (Harwood Academic Publishers)

He also holds the positions of:

• Responsible for transplants of the Italian Group for the Study of Lymphomas - GISL
• Member of the Scientific Committee of the Italian Lymphoma Intergroup - F.I.L.
• President of the European Congress for Transplantation (EBMT Courmayeur, 1996)
• President of the International Congress of Experimental Hematology (ISEH Montecarlo, 1999)
• President, together with PL Zinzani, of the Post-ASH Educational Meeting organized every year since 2008 and attended by over 700 Italian hematologists
• President of the "Postgraduate Lymphoma Conference" attended by the most important international experts in lymphoma every year
• Scientific Coordinator of the "Postgraduate Leukemia Conference", attended by the most important experts in biology and therapy of acute and chronic leukemia and myeloproliferative syndromes
• President of the Association of Hemato-Oncological Research (AREO)

He is the Knight of the Republic and was recently offered reading and a plaque by the Italian Lymphoma Foundation for his intense scientific activity in lymphomas. In February 2019, he was given the "MERIT AWARD" in Mannheim, Germany, by the European Leukemia Research Group (LEUKEMIANET Group) during its plenary meeting.